With the Ariad deal, Takeda gets access to the leukemia drug – Iclusig – and a new lung cancer treatment drug, Brigatinib – which is expected to be approved by the US FDA by April.
Both of these drugs will give the Japanese company a bigger foothold in the US market, and allow it to sell these drugs in Asia. Commercial cancer treatments are highly sought after by drugmakers but the pricing of these drugs is also highly sensitive. Ariad came under fire from US politicians including Bernie Sanders for raising the price of Iclusig four times in one year. Takeda has paid a massive premium for Ariad. It will be under scrutiny in the US if it raises prices of its drugs to help it claw back what its spent.